ALNY
Alnylam Pharmaceuticals
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: ALNY
- PEG Ratio
As of Aug 1, 2026, ALNY's PEG ratio of 0.09 reflects its valuation relative to its growth rate. This result reflects a P/E ratio of 33.69 measured against EPS growth of 376.0%. When benchmarked against the trailing 4-quarter average of 1.93, ALNY's PEG ratio reflects a 95% decrease.
ALNY PEG ratio history
Alnylam Pharmaceuticals PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.79 | 166.38 | 209.6% |
| 2024 | N/A | N/A | 38.1% |
| 2023 | N/A | N/A | 62.2% |
| 2022 | N/A | N/A | -29.2% |
| 2021 | N/A | N/A | 3.5% |
| 2020 | N/A | N/A | 8% |
| 2019 | N/A | N/A | -7.1% |
| 2018 | N/A | N/A | -39.7% |
| 2017 | N/A | N/A | -13.2% |
| 2016 | N/A | N/A | -38.8% |
| 2015 | N/A | N/A | 28.9% |
| 2014 | N/A | N/A | -234.5% |
| 2013 | N/A | N/A | 31.3% |
| 2012 | N/A | N/A | -55.1% |
| 2011 | N/A | N/A | -30.8% |
Alnylam Pharmaceuticals PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.13 | 49.35 | 376% |
| Mar 2026 | 0.22 | 76.59 | 341.3% |
| Dec 2025 | 0.79 | 166.38 | 209.6% |
| Sep 2025 | 6.57 | 800 | 121.8% |
| Jun 2025 | N/A | N/A | -294.6% |
| Mar 2025 | N/A | N/A | 32.2% |
| Dec 2024 | N/A | N/A | 38.1% |
| Sep 2024 | N/A | N/A | 36.5% |
| Jun 2024 | N/A | N/A | 93.5% |
| Mar 2024 | N/A | N/A | 69.6% |
| Dec 2023 | N/A | N/A | 62.2% |
| Sep 2023 | N/A | N/A | 57.9% |
| Jun 2023 | N/A | N/A | -5.4% |
| Mar 2023 | N/A | N/A | -16% |
| Dec 2022 | N/A | N/A | -29.2% |
ALNY average PEG ratio chart
PEG comparison
With a PEG of 0.09, ALNY ranks lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 0.56, Alnylam Pharmaceuticals's PEG is 84% lower.
ALNY EPS growth
ALNY Price vs fair value
ALNY PEG vs peers
Among its peer stocks REGN and TEVA, ALNY's PEG ratio comes in lower.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| ALNY Alnylam Pharmaceuticals Inc | 0.09 | $28.86B |
| TEVA Teva- Pharmaceutical Industries Ltd | 0.1 | $39.65B |
| SRPT Sarepta Therapeutics Inc | 0.21 | $1.61B |
| REGN Regeneron Pharmaceuticals Inc | 45.5 | $78.59B |
| ARWR Arrowhead Pharmaceuticals Inc | N/A | $11.95B |
| OPK Opko Health Inc | N/A | $981.42M |
| NVS Novartis AG | N/A | $293.47B |
Frequently asked questions
What is Alnylam Pharmaceuticals's PEG ratio?
ALNY has a PEG ratio of 0.09, per Aug 1, 2026 data.
Why is Alnylam Pharmaceuticals's PEG ratio so low?
At 0.09, ALNY's PEG ratio suggests the stock may be undervalued given its growth rate.
How is ALNY's PEG ratio calculated (Alnylam Pharmaceuticals PEG ratio formula)?
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Aug 1, 2026, Alnylam Pharmaceuticals carries a PE ratio of 33.69. Earnings grew at 376.0% over the TTM period ending Jun 2026. Applying the formula, this yields a PEG ratio of 0.09. PEG RATIO(0.09) = PE RATIO(33.69) / EPS GROWTH(376.0%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.